Its alliance with a successful foreign biotech could be decisive for the stock. Summit Therapeutics' (SMMT -8.44%) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the company and its main collaborator. Now the question is whether Summit can continue wowing investors as its candidates approach their shot at commercialization. But you might look at its pipeline and conclude that the biotech is a one-trick ...

One of them is performing much better than the other this year. The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics (VKTX -1.11%) and Summit Therapeutics (SMMT -8.44%), two clinical-stage drugmakers, have seen their shares skyrocket. The reason? Both companies announced promising clinical progress for their leading pipeline candidates. While there's still some way to go before launching their products, it's hard to argue with the result ...

These relatively small companies are developing new cancer therapies that could generate billions in annual sales. Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares of Summit Therapeutics and Instil Bio marched over 700% higher. These stocks have outperformed because the new drug candidates they're developing could become some of the most successful cancer trea ...

How long will the momentum last? Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue to grow incredibly fast. Nvidia's shares are up by 137% this year. Some companies have performed even better, including one many investors may never have heard about: Summit Therapeutics (SMMT 5.31%). The biotech's performance this year makes Nvidia's look mediocre: Summit's shar ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study. Thrill-seeking investors can get their fill with the rollercoaster rides provided by clinical-stage biotech stocks. Just look at Summit Therapeutics (SMMT -6.33%). By May 7, 2024, Summit Therapeutics stock had more than doubled year to date. Only three weeks later, the biopharmaceutical company's share price was down 8% year to date -- a huge swing in the wrong di ...

There's a lot of hope for ivonescimab, but are investors being a bit too bullish? If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for owning a piece of the business. And in some cases, those valuations can appear extreme, especially when you consider the risk that investors are taking on. One biotech company which may be the ultimate example of that right now is Summit Therapeutics (SMMT -2.02%). Its market capitalization eclipsed $23 bil ...

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious competitor. Sales of Keytruda from Merck reached $25 billion last year thanks to its position as a standard first line of treatment for most patients newly diagnosed with the most common form of lung can ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers. Shares of Summit Therapeutics (SMMT 8.32%) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence. A biotech stock surging that much usually means a new blockbuster drug candidate either posted good trial data or was approved for use. That's exactly what happened with Summit's lung cancer antibody I ...

This high-flying biotech stock is moving even higher -- and for good reason. Shares of Summit Therapeutics (SMMT 22.16%) were soaring 22.5% higher as of 11:18 a.m. ET on Thursday. The gain came after the clinical-stage biopharmaceutical company revealed that it entered into agreements with several biotech institutional and individual accredited investors for the sale of over 10.3 million shares for roughly $235 million in a private placement. Investors were undoubtedly especially glad to see key insiders ag ...

Summit Therapeutics Inc. NASDAQ: SMMT has seen a meteoric rise this month, surging over 106% after releasing positive clinical trial results for its experimental cancer therapy. Year-to-date, the stock is up a staggering 769%. This sharp uptick in share price was driven by the results of a Phase 3 study presented on September 8 at the 2024 World Conference on Lung Cancer in San Diego, which suggests its lead drug candidate, Ivonescimab, could significantly outperform the current standard of care for lung ca ...